Glenmede Trust’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-367,320
| Closed | -$10.5M | – | 1421 |
|
|
2024
Q2 | $10.5M | Buy |
367,320
+3,915
| +1% | +$111K | 0.05% | 345 |
|
|
2024
Q1 | $10.6M | Buy |
363,405
+26,414
| +8% | +$811K | 0.05% | 355 |
|
|
2023
Q4 | $11.4M | Sell |
336,991
-10,231
| -3% | -$299K | 0.06% | 332 |
|
|
2023
Q3 | $10.7M | Buy |
347,222
+51,877
| +18% | +$1.87M | 0.06% | 324 |
|
|
2023
Q2 | $12M | Buy |
295,345
+569
| +0.2% | +$23.5K | 0.07% | 298 |
|
|
2023
Q1 | $12M | Buy |
294,776
+113,616
| +63% | +$4.52M | 0.07% | 301 |
|
|
2022
Q4 | $6.99M | Sell |
181,160
-22,362
| -11% | -$1.09M | 0.04% | 374 |
|
|
2022
Q3 | $10.8M | Sell |
203,522
-24,447
| -11% | -$1.36M | 0.07% | 301 |
|
|
2022
Q2 | $13.3M | Sell |
227,969
-24,764
| -10% | -$1.62M | 0.08% | 286 |
|
|
2022
Q1 | $19.3M | Buy |
252,733
+53,896
| +27% | +$3.59M | 0.09% | 253 |
|
|
2021
Q4 | $12M | Sell |
198,837
-428
| -0.2% | -$23.6K | 0.06% | 354 |
|
|
2021
Q3 | $11.2M | Sell |
199,265
-2,539
| -1% | -$146K | 0.06% | 342 |
|
|
2021
Q2 | $12.2M | Sell |
201,804
-694
| -0.3% | -$43.9K | 0.06% | 324 |
|
|
2021
Q1 | $14.2M | Sell |
202,498
-53,915
| -21% | -$3.85M | 0.08% | 284 |
|
|
2020
Q4 | $15.3M | Sell |
256,413
-20,072
| -7% | -$1.18M | 0.08% | 265 |
|
|
2020
Q3 | $16.6M | Buy |
276,485
+57,374
| +26% | +$3.33M | 0.1% | 230 |
|
|
2020
Q2 | $11.5M | Buy |
219,111
+216,746
| +9,165% | +$9.06M | 0.07% | 288 |
|
|
2020
Q1 | $107K | Hold |
2,365
| – | – | ﹤0.01% | 1397 |
|
|
2019
Q4 | $107K | Sell |
2,365
-8,187
| -78% | -$348K | ﹤0.01% | 1397 |
|
|
2019
Q3 | $401 | Buy |
10,552
+8,760
| +489% | +$350K | ﹤0.01% | 953 |
|
|
2019
Q2 | $77 | Hold |
1,792
| – | – | ﹤0.01% | 1493 |
|
|
2019
Q1 | $68 | Hold |
1,792
| – | – | ﹤0.01% | 1543 |
|
|
2018
Q4 | $77 | Buy |
+1,792
| New | +$83.6K | ﹤0.01% | 1429 |
|
|
2018
Q2 | – | Sell |
-145
| Closed | -$6K | – | 2217 |
|
|
2018
Q1 | $6K | Hold |
145
| – | – | ﹤0.01% | 2351 |
|
|
2017
Q4 | $6K | Buy |
145
+66
| +84% | +$2.62K | ﹤0.01% | 2351 |
|
|
2017
Q3 | $2K | Buy |
+79
| New | +$3.18K | ﹤0.01% | 2589 |
|
|
2017
Q1 | – | Sell |
-600
| Closed | -$19K | – | 2727 |
|
|
2016
Q4 | $19K | Sell |
600
-135
| -18% | -$4.5K | ﹤0.01% | 1911 |
|
|
2016
Q3 | $25K | Buy |
735
+315
| +75% | +$12.3K | ﹤0.01% | 1868 |
|
|
2016
Q2 | $14K | Buy |
420
+230
| +121% | +$11.3K | ﹤0.01% | 2018 |
|
|
2016
Q1 | $10K | Buy |
+190
| New | +$11.1K | ﹤0.01% | 2047 |
|
|
2013
Q3 | – | Sell |
-16,556
| Closed | -$480K | – | 2251 |
|
|
2013
Q2 | $480K | Buy |
+16,556
| New | +$479K | 0.01% | 793 |
|
Other funds holding PCRX
DPCM
Glenmede Trust's PCRX Position: Q3 2024 in Review
Glenmede Trust sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 367,320 shares — an estimated $10.5M sold.
Glenmede Trust first reported a position in PCRX in Q2 2013 and held it in 31 quarters. The position peaked at $19.3M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.
- Glenmede Trust reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
- Glenmede Trust sold 367,320 Pacira BioSciences shares in Q3 2024, an estimated $10.5M.
- Glenmede Trust first reported a position in Pacira BioSciences in Q2 2013 and held it in 31 quarters.
- Glenmede Trust's Pacira BioSciences position peaked at $19.3M in Q1 2022.
- 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.
Based on Glenmede Trust's 13F filing for Q3 2024, filed 13 Nov 2024.